Stay updated on Clinical Trial: TTF+IO±CTLA-4 for Recurrent Glioblastoma
Sign up to get notified when there's something new on the Clinical Trial: TTF+IO±CTLA-4 for Recurrent Glioblastoma page.

Latest updates to the Clinical Trial: TTF+IO±CTLA-4 for Recurrent Glioblastoma page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2; no changes to study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check19 days agoChange DetectedRevision label updated from v3.4.0 to v3.4.1, a minor frontend/version control change with no impact on study data, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check33 days agoChange DetectedUI changes include the glossary show/hide options and updated text such as 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0', while the corresponding older labels are removed or renamed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check41 days agoChange DetectedThe page shows a minor site revision update from v3.3.3 to v3.3.4 with no changes to core content or study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check69 days agoChange DetectedThe page now includes a Locations section with Florida as a site, and the previous 'Florida Locations' entry and the HHS Vulnerability Disclosure footer link were removed.SummaryDifference0.2%

- Check91 days agoChange DetectedThe site revision was updated from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Clinical Trial: TTF+IO±CTLA-4 for Recurrent Glioblastoma
Enter your email address, and we'll notify you when there's something new on the Clinical Trial: TTF+IO±CTLA-4 for Recurrent Glioblastoma page.